Received: 18 April 2020
Accepted: 25 March 2021
First Online: 7 April 2021
: No institutional review board approval was required for this study, as only deidentified data obtained with permission from NCI was analyzed. The submission does not meet the definition of “human subject research” as defined by the regulations 45 CFR46.102 (e); data was neither obtained via intervention/interaction with a living individual by the investigator, nor was identifiable.
: Not applicable.
: The authors declare that they have no competing interests. CYW is a consultant to Allergan/AbbVie, Inc.; Alcon, Inc.; Alimera Sciences, Inc.; Regeneron; REGENXBIO; Genentech; Novartis; Dutch Ophthalmic Research Center.